Global Custom Market Research Reports Provider Company

phone

Audentes Therapeutics Inc (BOLD) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

  • Published Date: 23 Oct 2018
  • Number of Pages: 62
  • Category: Company Profile
  • Country: United States of America
Summary

Audentes Therapeutics Inc (Audentes) is a biotechnology company that focuses on the development and commercialization of gene therapy products for serious and life-threatening rare diseases. The companys pipeline products include AT132, intended for the treatment of X-linked myotubular myopathy; AT982, for the treatment of Pompe disease; AT342, for the treatment of crigler-najjar syndrome; and AT307, for the treatment of CASQ2-related catecholaminergic polymorphic ventricular tachycardia. Audentes offers viral vectors for gene therapy most frequently and track record off adeno-associated virus vector (AAV) in non-pathogenic product, among others. The company has collaboration with various patient, research and medical communities to advance its product candidates. Audentes is headquartered in San Francisco, California, the US.

Audentes Therapeutics Inc (BOLD) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the companys Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals - Analysis of the companys financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the companys major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Companys (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the companys operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.

Reasons To Buy


Get detailed information on the companys financial deals that enable you to understand the companys expansion/divestiture and fund requirements
- The profile enables you to analyze the companys financial deals by region, by year, by business segments and by type, for a five year period.

Understand the companys business segments expansion / divestiture strategy
- The profile presents deals from the companys core business segments perspective to help you understand its corporate strategy.

Access elaborate information on the companys recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Companys key financial metrics and ratios.

Equip yourself with detailed information about the companys operations to identify potential customers and suppliers.
- The profile analyzes the companys business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.
Publisher Name : GlobalData


List of Tables 5
List of Figures 5
Audentes Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Audentes Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Audentes Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Audentes Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Audentes Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Audentes Therapeutics Inc, Pharmaceuticals & Healthcare, Deal Details 12
Venture Financing 12
Audentes Therapeutics Raises USD65 Million in Series C Financing Round 12
Audentes Therapeutics Raises USD42.5 Million in Series B Financing 15
Cardiogen Sciences Secures USD0.52 Million in Venture Funding 17
Audentes Therapeutics Raises US$30 Million In Series A Financing 18
Audentes Therapeutics Raises Funds through Seed Financing 20
Partnerships 21
Audentes Therapeutics Amends Co-Development with University of Pennsylvania 21
Audentes Therapeutics Enters Into Co-Development Agreement With Genethon For AT001 22
Licensing Agreements 23
Audentes Therapeutics Enters Into Licensing Agreement With RegenxBio 23
Audentes Therapeutics Enters into Licensing Agreement with RegenxBio for CPVT 24
Audentes Therapeutics Amends its Licensing Agreement with University of Florida Research Foundation 26
Cardiogen Sciences Enters into Licensing Agreement with Fondazione Salvatore Maugeri 27
Audentes Therapeutics Enters Into Licensing Agreement with ReGenX Biosciences 28
Equity Offering 29
Audentes Therapeutics Prices Public Offering of Shares for USD150.8 Million 29
Audentes Therapeutics Raises USD231 Million in Public Offering of Shares 31
Audentes Therapeutics to Raise up to USD75 Million in Public Offering of Shares 33
Audentes Therapeutics Raises USD86.3 Million in Public Offering of Shares 34
Audentes Therapeutics Raises USD75 Million in IPO 36
Acquisition 37
Audentes Therapeutics Acquires Cardiogen Sciences 37
Audentes Therapeutics Inc - Key Competitors 38
Audentes Therapeutics Inc - Key Employees 39
Audentes Therapeutics Inc - Locations And Subsidiaries 40
Head Office 40
Other Locations & Subsidiaries 40
Recent Developments 41
Financial Announcements 41
Aug 07, 2018: Audentes Therapeutics Reports Second Quarter 2018 Financial Results 41
May 09, 2018: Audentes Therapeutics Reports First Quarter 2018 Financial Results and Provides Corporate Update 43
Mar 08, 2018: Audentes Therapeutics Announces Fourth Quarter 2017 And Full Year Financial Results 45
Nov 14, 2017: Audentes Therapeutics Reports Third Quarter 2017 Financial Results and Provides Corporate Update 46
Aug 10, 2017: Audentes Therapeutics Reports Second Quarter 2017 Financial Results and Provides Corporate Update 47
May 11, 2017: Audentes Therapeutics Reports First Quarter 2017 Financial Results and Provides Corporate Update 49
Mar 09, 2017: Audentes Therapeutics Reports Fourth Quarter and Full Year 2016 Financial Results and Provides Corporate Update 51
Jan 09, 2017: Audentes Therapeutics Provides Full Year 2017 Strategic Outlook and Financial Guidance 54
Corporate Communications 56
Oct 03, 2018: Audentes Therapeutics announces co-founder and chief executive Officer Matthew R. Patterson appointed chairman of the alliance for regenerative medicine 56
May 08, 2018: Audentes Therapeutics Announces the Promotion of Natalie Holles to President and Chief Operating Officer 57
Dec 13, 2017: Audentes Therapeutics Appoints Mark A. Goldberg, M.D. to its Board of Directors 58
Jun 13, 2017: Audentes Therapeutics Appoints Jennifer Jarrett to Board of Directors 59
May 08, 2017: Audentes Therapeutics Announces Appointment of John T. Gray, Ph.D. to Senior Vice President and Chief Scientific Officer 60
Product News 61
04/30/2018: Audentes Therapeutics Announces Presentation of Data at the 21st Annual Meeting of the American Society of Gene and Cell Therapy 61
Appendix 62
Methodology 62
About GlobalData 62
Contact Us 62
Disclaimer 62

List Of Tables


Audentes Therapeutics Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Audentes Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Audentes Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Audentes Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Audentes Therapeutics Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Audentes Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Audentes Therapeutics Raises USD65 Million in Series C Financing Round 12
Audentes Therapeutics Raises USD42.5 Million in Series B Financing 15
Cardiogen Sciences Secures USD0.52 Million in Venture Funding 17
Audentes Therapeutics Raises US$30 Million In Series A Financing 18
Audentes Therapeutics Raises Funds through Seed Financing 20
Audentes Therapeutics Amends Co-Development with University of Pennsylvania 21
Audentes Therapeutics Enters Into Co-Development Agreement With Genethon For AT001 22
Audentes Therapeutics Enters Into Licensing Agreement With RegenxBio 23
Audentes Therapeutics Enters into Licensing Agreement with RegenxBio for CPVT 24
Audentes Therapeutics Amends its Licensing Agreement with University of Florida Research Foundation 26
Cardiogen Sciences Enters into Licensing Agreement with Fondazione Salvatore Maugeri 27
Audentes Therapeutics Enters Into Licensing Agreement with ReGenX Biosciences 28
Audentes Therapeutics Prices Public Offering of Shares for USD150.8 Million 29
Audentes Therapeutics Raises USD231 Million in Public Offering of Shares 31
Audentes Therapeutics to Raise up to USD75 Million in Public Offering of Shares 33
Audentes Therapeutics Raises USD86.3 Million in Public Offering of Shares 34
Audentes Therapeutics Raises USD75 Million in IPO 36
Audentes Therapeutics Acquires Cardiogen Sciences 37
Audentes Therapeutics Inc, Key Competitors 38
Audentes Therapeutics Inc, Key Employees 39
Audentes Therapeutics Inc, Subsidiaries 40

List Of Figures


Audentes Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Audentes Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Audentes Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Audentes Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Audentes Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Audentes Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Audentes Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Audentes Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Autolus Therapeutics Plc (Autolus), formerly Autolus Therapeutics Limited is a clinical-stage biopharmaceutical company which offers programmed T cell immunotherapies for the treatment of hematological cancers and solid tumors. The company

View Report

BeyondSpring Inc (BeyondSpring) is a clinical stage biopharmaceutical company focused on the development of immune-oncology cancer therapies. The company offers lead compound, Plinabulin, is derived from a natural compound which

View Report

Gabather AB (Gabather) is a developer of new drug candidates for the treatment of central nervous system diseases. The company spans its expertise in the development of anti-psychotics, anti-depressants and

View Report
There is no reviews available for this report

Select License Type

Delivery Details

Delivery Details : Electronic files (PDF) of market research reports will dispatched within 12 to 24 hours. (Mon-Fri IST)

Customized Report

If a particular report is not as per your requirement you can ‎choose "Customized Report". To visit click on -

Custom Research Reports